Skip to main content
    T

    Tscan Therapeutics Inc (TCRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.15
    -0.02 (-9.65%)

    Market Cap: $10.89M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Tscan Therapeutics Inc (TCRX) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Tscan Therapeutics (TCRX) trades at 3.6x sales and 0.5x book value. Its P/S of 3.6x is below its 5-year median of 12.7x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/EN/A
    Price to sales3.6x
    Price to book0.5x
    EV/FCF0.2x
    PEGN/A
    FCF yield-591.9%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S3.6x12.7xN/A
    P/B0.5x1.1xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 5 year ends shown, its P/S ranged from 1.9x in 2021 to 121.4x in 2024.

    Year endPriceP/SP/B
    2025$1.0012.6x1.1x
    2024$3.04121.4x1.5x
    2023$5.8312.6x3.7x
    2022$1.553.1x0.4x
    2021$4.501.9x0.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TCRX

    Is TCRX stock overvalued?

    GNG's valuation label for TCRX is Undervalued.

    What is TCRX's price to sales ratio?

    Tscan Therapeutics has a price to sales ratio of 3.6x.